Your first taste of
Singapore blue chips
from just S$100 a month!

With POSB Invest-Saver, you can now potentially grow your long-term savings through a low-cost investment. From just S$100 a month, you can invest in the Nikko AM Singapore STI ETF# - an Exchange Traded Fund that tracks the performance of Singapore’s top 30^ blue-chip companies including Singapore Exchange, Singapore Airlines and Singapore Press Holdings.


++ Subject to change

+ Click here for the prospectus/product highlight sheet and here for the full T&Cs

# The Nikko AM Singapore STI ETF tracks the performance of the FTSE Straits Times Index (‘STI’), which is compiled and calculated by FTSE International Limited and represents the top 30 companies listed on the SGX-ST ranked by market capitalization. The constituents of the STI are reviewed every half-yearly.

^ Based on SGX-ST’s ranking by market capitalization

* Based on 1% sales charge on a monthly investment amount of S$100.

Important Notes:
POSB Invest-Saver is not included under the CPF Investment Scheme and Supplementary Retirement Scheme. Investment in the POSB Invest-Saver is by cash only.

Nikko AM Singapore STI ETF is a collective investment scheme that is managed by Nikko Asset Management Asia Limited.

This publication is for general circulation only and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person. The value of the units and the income accruing to the units purchased, if any, may fall or rise. Any past performance, projection, forecast or simulation of results is not necessarily indicative of the future or likely performance of any investment. Investors should seek advice from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objective, financial situation or particular needs of each person before making a commitment to purchase the investment product. If you do not wish to seek financial advice, please consider carefully whether the product is suitable for you. Investors should read the relevant product’s offer documents (including the prospectus and Product Highlights Sheet, if any), available at our branches and website, before deciding to subscribe for or purchase any product.